Viking Therapeutics (VKTX) Change in Accured Expenses (2014 - 2026)

Viking Therapeutics has disclosed Change in Accured Expenses across 13 years of filings, most recently posting $15.9 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $15.9 million, up 376.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.8 million (up 275.25% YoY), and the FY2025 annual result was $6.2 million, up 6.05% from the prior year.
• Change in Accured Expenses came in at $15.9 million for Q1 2026 at Viking Therapeutics, up from $2.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $15.9 million in Q1 2024 to a low of -$13.6 million in Q2 2024.
• The 5-year median for Change in Accured Expenses is $694000.0 (2022), against an average of $1.9 million.
• Across the five-year window, Change in Accured Expenses sank 862.72% in 2023 and jumped 6472.88% in 2024, its largest moves.
• Viking Therapeutics' Change in Accured Expenses stood at $2.5 million in 2022, then jumped by 57.26% to $3.9 million in 2023, then plunged by 299.8% to -$7.8 million in 2024, then surged by 126.37% to $2.1 million in 2025, then soared by 667.81% to $15.9 million in 2026.
• The last three Change in Accured Expenses figures came in at $15.9 million (Q1 2026), $2.1 million (Q4 2025), and -$4.8 million (Q3 2025), per Business Quant data.